Legal & General Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Legal & General Group’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,252	Closed	-$123K	–	3441
2022 Q4	$123K	Buy	+8,252	New	+$114K	﹤0.01%	2770
2021 Q2	–	Sell	-2,143	Closed	-$16K	–	3786
2021 Q1	$16K	Sell	2,143 -187	-8%	-$1.61K	﹤0.01%	3235
2020 Q4	$13K	Hold	2,330	–	–	﹤0.01%	3266
2020 Q3	$14K	Buy	2,330 +312	+15%	+$1.54K	﹤0.01%	3113
2020 Q2	$10K	Buy	+2,018	New	+$12.7K	﹤0.01%	3322
2019 Q3	–	Sell	-1,512	Closed	-$10K	–	3471
2019 Q2	$10K	Hold	1,512	–	–	﹤0.01%	3368
2019 Q1	$12K	Hold	1,512	–	–	﹤0.01%	3229
2018 Q4	$24K	Hold	1,512	–	–	﹤0.01%	3018
2018 Q3	$50K	Hold	1,512	–	–	﹤0.01%	2776
2018 Q2	$34K	Buy	+1,512	New	+$35.9K	﹤0.01%	2962

Legal & General Group's AVEO Position: Q1 2023 in Review

Legal & General Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 8,252 shares — an estimated $123K sold.

Legal & General Group first reported a position in AVEO in Q2 2018 and held it in 10 quarters. The position peaked at $123K in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Legal & General Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Legal & General Group sold 8,252 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $123K.
Legal & General Group first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2018 and held it in 10 quarters.
Legal & General Group's AVEO Pharmaceuticals, Inc. position peaked at $123K in Q4 2022.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Legal & General Group's 13F filing for Q1 2023, filed 15 May 2023.